Genentech and Hemophilia A Genentech and Hemophilia A

The coagulation cascade in hemophilia A.

The blood clotting process is controlled by a series of events that scientists call the coagulation cascade. The coagulation cascade is complicated because it involves a cast of important characters and many different pathways and connections. 5 It has taken scientists years to unlock its mysteries, and our understanding of the cascade is ever-evolving, even today.

In hemophilia A, one of the important characters, known as factor VIII, is either missing or at a low level. This interrupts the coagulation cascade and prevents blood from clotting. 6

Scientists are studying different approaches to continuing the coagulation cascade. The hope is that more research may offer more treatment options for people living with hemophilia A.

Genentech's Commitment to the Community Genentech's Commitment to the Community

We're learning from you.

We believe that it's not only the medicines we make, but the partnerships we build and the communities we form that can help lead to a healthier world. 

As we put our science to work, we look to the community to better understand your hopes, challenges, and needs.

Our Clinical Educators* embody our company philosophy to support the communities we serve. They are leading an effort to get involved and hear directly from those they aim to help. Their main role is to be an educational resource for patients and their loved ones. They are not sales representatives—they are here to serve you.

*Our Clinical Educators do not provide medical advice. Please talk to your healthcare provider for medical advice about your health or appropriate medical care.